Open access
Open access
Powered by Google Translator Translator

EBM & Clinical Trials

Analysis: Shifting, Overlapping and Expanding Use of “Precision Oncology” Terminology

16 Jun, 2020 | 07:46h | UTC

Shifting, overlapping and expanding use of “precision oncology” terminology: a retrospective literature analysis – BMJ Open

 


Opinion: John Ioannidis and Medical Tribalism in the Era of Covid-19

12 Jun, 2020 | 09:21h | UTC

Opinion: John Ioannidis and Medical Tribalism in the Era of Covid-19 – Undark

“The critical questions the Stanford professor is raising about Covid-19 have gotten lost amid partisan bickering”

 

 


MIT, Guided by Open Access Principles, Ends Elsevier Negotiations

12 Jun, 2020 | 08:57h | UTC

MIT, guided by open access principles, ends Elsevier negotiations – MIT News

Related: UC Terminates Subscriptions with World’s Largest Scientific Publisher in Push for Open Access (several resources on the subject)

 


Reporting of Financial Conflicts of Interest by Canadian Clinical Practice Guideline Producers

11 Jun, 2020 | 09:22h | UTC

Reporting of financial conflicts of interest by Canadian clinical practice guideline producers: a descriptive study – Canadian Medical Association Journal

 


The Pandemic Mixed up What Scientists Study – and Some Won’t go Back

8 Jun, 2020 | 04:26h | UTC

The pandemic mixed up what scientists study – and some won’t go back – Nature

 


Lancet, New England Journal Retract Covid-19 Studies, Including one That Raised Safety Concerns About Malaria Drugs

5 Jun, 2020 | 05:07h | UTC

STAT: Lancet, New England Journal retract Covid-19 studies, including one that raised safety concerns about malaria drugs

Science: Two elite medical journals retract coronavirus papers over data integrity questions

NEJM: Retraction: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2007621.

The Lancet: Retraction: “Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis”

 


Challenge Trials—Could Deliberate Coronavirus Exposure Hasten Vaccine Development?

5 Jun, 2020 | 05:01h | UTC

Challenge Trials—Could Deliberate Coronavirus Exposure Hasten Vaccine Development? – JAMA

Related: Opinion: Ethical Guidelines for Deliberately Infecting Volunteers with COVID-19 to Speed Vaccine Development (other commentaries on the subject)

 


Scientists’ Worlds Will Shrink in the Wake of the Pandemic

5 Jun, 2020 | 04:55h | UTC

Scientists’ worlds will shrink in the wake of the pandemic – Nature

 


The Coronavirus Outbreak Could Make It Quicker and Easier to Trial Drugs

5 Jun, 2020 | 04:54h | UTC

The coronavirus outbreak could make it quicker and easier to trial drugs – Nature

 


Will the Pandemic Permanently Alter Scientific Publishing?

4 Jun, 2020 | 05:01h | UTC

Will the pandemic permanently alter scientific publishing? – Nature

 


How Scientific Conferences Will Survive the Coronavirus Shock

4 Jun, 2020 | 04:59h | UTC

How scientific conferences will survive the coronavirus shock – Nature

 


Expression of Concern Published by the NEJM Regarding the Study on the Effect of Preexisting Treatment with ACE Inhibitors and ARBs on Covid-19

3 Jun, 2020 | 03:46h | UTC

Editorial: Expression of Concern: Mehra MR et al. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2007621 – New England Journal of Medicine

See also: An open letter to Mehra et al and The New England Journal of Medicine – Zenodo

Commentary: Top medical journals raise concerns about data in two studies related to Covid-19 – STAT

“We have asked the authors to provide evidence that the data are reliable. In the interim and for the benefit of our readers, we are publishing this Expression of Concern about the reliability of their conclusions.”

 


Expression of Concern Published by The Lancet Regarding the Paper on Hydroxychloroquine and Chloroquine Published on May 22, 2020

3 Jun, 2020 | 03:51h | UTC

Expression of concern: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis – The Lancet

See also: An Open Letter to Mehra et al and The Lancet (further commentaries on the subject)

Commentary: Top medical journals raise concerns about data in two studies related to Covid-19 – STAT

“we are issuing an Expression of Concern to alert readers to the fact that serious scientific questions have been brought to our attention. We will update this notice as soon as we have further information.”

 


Remdesivir Shows Modest Improvement in Moderate COVID-19 Patients

2 Jun, 2020 | 04:59h | UTC


An Open Letter to Mehra et al and The Lancet

1 Jun, 2020 | 03:58h | UTC

An open letter to Mehra et al and The Lancet – Zenodo

See also: Disputed Hydroxychloroquine Study Brings Scrutiny to Surgisphere – The Scientist AND A Study Out of Thin Air – Medicine (Un)Censored

 


Perspective: Will Evidence-Based Medicine Survive COVID-19?

1 Jun, 2020 | 03:56h | UTC

Will Evidence-Based Medicine Survive COVID-19? – Boston Review

 


Opinion: Using Controlled Trials to Resolve Key Unknowns About Policy During the COVID-19 Pandemic

29 May, 2020 | 03:27h | UTC

Using Controlled Trials to Resolve Key Unknowns About Policy During the COVID-19 Pandemic – JAMA

 


Conducting Clinical Research During the COVID-19 Pandemic: Protecting Scientific Integrity

29 May, 2020 | 03:26h | UTC

Conducting Clinical Research During the COVID-19 Pandemic: Protecting Scientific Integrity – JAMA

 


Review of Trials Currently Testing Treatment and Prevention of COVID-19

28 May, 2020 | 09:48h | UTC

Review of trials currently testing treatment and prevention of COVID-19 – Clinical Microbiology and Infection

 


WHO: Revealing the Toll of COVID-19 – A Technical Package for Rapid Mortality Surveillance and Epidemic Response

27 May, 2020 | 02:48h | UTC

Revealing the toll of COVID-19: A technical package for rapid mortality surveillance and epidemic response – World Health Organization

 

Related Commentary on Twitter

 


Perspective: The Totality of the Evidence, by Dr. John Ioannidis

27 May, 2020 | 02:29h | UTC

The Totality of the Evidence – Boston Review

See other interesting perspectives from the Boston Review: Models v. Evidence AND Good Science Is Good Science

“Given what we know now, it is reasonable to consider alternatives to population-wide lockdown, even as we focus on protecting those most at risk and support health care systems to care for patients who are sick.”

 


Preprinting a Pandemic: The Role of Preprints in the COVID-19 Pandemic

27 May, 2020 | 02:25h | UTC

Preprinting a pandemic: the role of preprints in the COVID-19 pandemic – bioRxiv

 


Reasons to Worry Less About the Explosion of Preprints

27 May, 2020 | 02:24h | UTC

Reasons to Worry Less About the Explosion of Preprints – Absolutely Maybe Blog

 


Perspective: “Here’s What Needs to Happen Before We Can All Get Vaccinated for COVID-19”

26 May, 2020 | 09:45h | UTC

Here’s what needs to happen before we can all get vaccinated for COVID-19 – CBC

 


Impact of COVID-19 on Oncology Clinical Trials

26 May, 2020 | 09:40h | UTC

Impact of COVID-19 on oncology clinical trials – Nature Reviews Drug Discovery

Commentary: More Than 200 International Cancer Trials Suspended Due to COVID-19 – Medscape (free registration required)

 


Stay Updated in Your Specialty

 

No spam, just news.